McIlraith Ian, Strasfeld Maurice, Colev George, Hutnik Cindy M L
Ivey Eye Institute, University of Western Ontario, London, Ontario, Canada.
J Glaucoma. 2006 Apr;15(2):124-30. doi: 10.1097/00061198-200604000-00009.
To investigate the efficacy and safety of selective laser trabeculoplasty as an initial treatment for newly diagnosed open-angle glaucoma, and its role as adjunctive therapy.
A prospective multicenter nonrandomized clinical trial was performed. Patients with newly diagnosed open-angle glaucoma or ocular hypertension were assigned to the primary (selective laser trabeculoplasty) treatment group or the control (latanoprost) group according to patient choice. Both groups were followed up at 1, 3, 6, and 12 months. A secondary treatment group was also included to study the efficacy of selective laser trabeculoplasty for patients intolerant of medical therapy or in whom such therapy was unsuccessful, with or without a history of previous argon laser trabeculoplasty.
One hundred eyes (61 patients) were enrolled, 74 in the primary treatment group and 26 in the control group. The average absolute and percent reductions in intraocular pressure for the primary treatment group were 8.3 mm Hg or 31.0%, compared with 7.7 mm Hg or 30.6% for the control group (P = 0.208 and P = 0.879). The responder rates (20% pressure reduction) were 83% and 84% for the primary and control groups, respectively. There were no differences in intraocular pressure lowering with selective laser trabeculoplasty on the basis of angle pigmentation. A modest contralateral effect was observed in the untreated fellow eyes of patients undergoing selective laser trabeculoplasty.
Selective laser trabeculoplasty was found to be equally efficacious as latanoprost in reducing intraocular pressure in newly diagnosed open-angle glaucoma and ocular hypertension over 12 months, independent of angle pigmentation. Nonsteroidal antiinflammatory therapy had similar efficacy to steroids after laser therapy. These findings support the consideration of selective laser trabeculoplasty as a first-line treatment for newly diagnosed open-angle glaucoma or ocular hypertension.
探讨选择性激光小梁成形术作为新诊断开角型青光眼初始治疗的疗效和安全性及其辅助治疗作用。
进行了一项前瞻性多中心非随机临床试验。新诊断的开角型青光眼或高眼压症患者根据自身选择被分配至主要(选择性激光小梁成形术)治疗组或对照组(拉坦前列素)。两组均在1、3、6和12个月时进行随访。还纳入了一个二级治疗组,以研究选择性激光小梁成形术对不耐受药物治疗或药物治疗无效患者的疗效,无论其有无氩激光小梁成形术史。
共纳入100只眼(61例患者),主要治疗组74只眼,对照组26只眼。主要治疗组眼压的平均绝对降低值和降低百分比分别为8.3 mmHg或31.0%,对照组为7.7 mmHg或30.6%(P = 0.208和P = 0.879)。主要治疗组和对照组的眼压应答率(降低20%)分别为83%和84%。基于房角色素沉着情况,选择性激光小梁成形术在降低眼压方面无差异。在接受选择性激光小梁成形术的患者未治疗的对侧眼中观察到适度的对侧效应。
研究发现,在12个月内,选择性激光小梁成形术在降低新诊断开角型青光眼和高眼压症患者眼压方面与拉坦前列素同样有效,且与房角色素沉着无关。激光治疗后,非甾体抗炎治疗与类固醇治疗疗效相似。这些发现支持将选择性激光小梁成形术作为新诊断开角型青光眼或高眼压症的一线治疗方法。